Could your own fat cells fight Alzheimer's? new trial aims to find out

NCT ID NCT07205601

Not yet recruiting Disease control Sponsor: Regeneration Biomedical, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether repeated injections of a patient's own fat-derived stem cells into the brain can slow the progression of mild to moderate Alzheimer's disease. 115 participants will receive either the stem cells or a placebo every two months for a total of six doses. The main goal is to see if the treatment preserves memory and daily living skills better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patient's own fat-derived stem cells (RB-ADSC)
What this could lead to: If it works, this could slow memory loss and daily function decline in people with mild to moderate Alzheimer's disease.
What could go wrong: This is an early Phase 2 trial with only 115 participants. The treatment involves injections into the brain, which carries risks like infection or bleeding. Previous positive results were from a smaller Phase 1 study and may not hold up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.